High-potency Class I to II topicals are frequently used first line to suppress inflammation and symptoms of itching. These agents are often useful as therapy for stage IA disease, but are often ...

SS is a leukemic form of cutaneous T-cell lymphoma, presenting with erythroderma ... and aggressive clinical course, with median survival around 32 months. Though morphologically similar to ...

is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company's lead candidate, HyBryte(TM ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

Skin biopsy specimens of three lesions on her back were consistent with cutaneous T-cell lymphoma (CTCL). On physical examination, she had erythematous patches and plaques with ill-defined borders ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Interim Results from FDA-Funded Study Reinforces HyBryte's Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix ...